PGGM Investments Sells 20,613 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

PGGM Investments trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 36.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,029 shares of the biopharmaceutical company's stock after selling 20,613 shares during the quarter. PGGM Investments' holdings in Regeneron Pharmaceuticals were worth $31,644,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in REGN. FMR LLC increased its position in Regeneron Pharmaceuticals by 7.3% in the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company's stock valued at $8,098,661,000 after acquiring an additional 669,517 shares during the period. Northern Trust Corp increased its position in Regeneron Pharmaceuticals by 3.3% in the 3rd quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company's stock valued at $878,271,000 after acquiring an additional 34,326 shares during the period. Morgan Stanley increased its position in Regeneron Pharmaceuticals by 2.7% in the 3rd quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company's stock valued at $799,061,000 after acquiring an additional 25,792 shares during the period. Bank of New York Mellon Corp increased its position in Regeneron Pharmaceuticals by 0.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 967,414 shares of the biopharmaceutical company's stock valued at $796,142,000 after acquiring an additional 2,666 shares during the period. Finally, American Century Companies Inc. increased its position in Regeneron Pharmaceuticals by 3.4% in the 3rd quarter. American Century Companies Inc. now owns 916,718 shares of the biopharmaceutical company's stock valued at $754,422,000 after acquiring an additional 30,050 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, EVP Marion Mccourt sold 1,000 shares of the firm's stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares of the company's stock, valued at $12,888,716.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Marion Mccourt sold 1,000 shares of the firm's stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares of the company's stock, valued at $12,888,716.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of the firm's stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares in the company, valued at $46,203,239.82. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,022 shares of company stock valued at $10,552,991. Corporate insiders own 8.83% of the company's stock.

Regeneron Pharmaceuticals Stock Down 0.8 %

Shares of Regeneron Pharmaceuticals stock traded down $7.48 during trading hours on Friday, reaching $883.20. The company's stock had a trading volume of 505,652 shares, compared to its average volume of 431,865. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The company has a market capitalization of $96.94 billion, a P/E ratio of 25.42, a P/E/G ratio of 2.56 and a beta of 0.11. The stock's fifty day simple moving average is $948.00 and its two-hundred day simple moving average is $894.04. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts' consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same period last year, the firm earned $10.96 earnings per share. The business's quarterly revenue was up .6% compared to the same quarter last year. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on REGN. UBS Group upped their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a "buy" rating in a research report on Wednesday, April 17th. Bank of America increased their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an "underperform" rating in a research report on Friday, April 12th. Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 13th. Sanford C. Bernstein assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an "outperform" rating and a $1,125.00 price objective for the company. Finally, StockNews.com cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 20th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $977.77.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.